Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited

Everest Medicines, through its wholly-owned subsidiary EverSea Medicines (Singapore) Pte. Ltd., has entered into a Share Purchase Agreement to acquire the entire equity interest in Hasten Biopharmaceuticals (SG) Pte. Ltd. from Hasten Biopharmaceuticals (Asia) Limited for USD250 million, payable in three installments. The acquisition includes MAH rights, trademark, and commercial rights for 14 branded chronic disease products across Asia Pacific, with the target recording normalized revenue of US$82.2 million and EBITDA of US$27.3 million for FY2025.